1303988-99-9Relevant academic research and scientific papers
Discovery of pyrazinone based compounds that potently inhibit the drug-resistant enzyme variant R155K of the hepatitis C virus NS3 protease
Belfrage, Anna Karin,Abdurakhmanov, Eldar,?kerblom, Eva,Brandt, Peter,Oshalim, Anna,Gising, Johan,Skogh, Anna,Neyts, Johan,Danielson, U. Helena,Sandstr?m, Anja
, p. 2603 - 2620 (2016)
Herein, we present the design and synthesis of 2(1H)-pyrazinone based HCV NS3 protease inhibitors with variations in the C-terminus. Biochemical evaluation was performed using genotype 1a, both the wild-type and the drug resistant enzyme variant, R155K. S
3-AMINO-PYRIDINES AS GPBAR1 AGONISTS
-
Page/Page column 97, (2012/09/22)
This invention relates to novel 3-aminopyridines of the formula wherein B1, B2 and R1 to R6 are as defined in the description and in the claims, as well as pharmaceutically acceptable salts thereof. These compounds are GPBAR1 agonists and can be used as medicaments for the treatment of diseases such as type II diabetes
